Article

An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis

Department of Neurology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 5.58). 10/2010; 81(10):1167-9. DOI: 10.1136/jnnp.2009.178293
Source: PubMed

ABSTRACT Voltage-gated potassium channel antibody-positive limbic encephalitis (VGKC+LE) frequently improves with immunotherapy, although the optimum regimen is unknown. The effectiveness of a combination immunomodulatory regimen was tested in consecutive VGKC+LE patients.
This was an open-label prospective study of nine VGKC+LE patients. All patients had plasma exchange (50 ml/kg), intravenous immunoglobulin (2 g/kg) and intravenous methylprednisolone (1 g×3), followed by maintenance oral prednisolone (1 mg/kg/day). Mycophenolate (2 g/day) was used in the first three patients. Assessments included serial clinical, cognitive, brain MRI and VGKC antibody testing.
Within 1 week, seizures and hyponatraemia remitted in all affected patients. Cognitive function improved in all patients within 3 months. MRI appearances improved substantially within 9 months, with remission of inflammation in the majority of patients. All achieved immunological remission with normal VGKC antibody titres within 1-4 months. Major adverse events of therapy included one septicaemia and one thrombosis on plasma exchange and one death from sepsis after incidental bowel surgery. One patient remains in remission after 40 months of follow up, 26 months after being off all treatment.
Our immunotherapy regimen was effective for the treatment of the clinical, cognitive and immunological features of VGKC+LE. Radiological improvement was seen in the majority. Pending randomised controlled trials, this regimen is proposed for the treatment of VGKC+LE.

0 Followers
 · 
163 Views
  • Source
    • "Plasma treatment was used in a few patients with steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) (also referred as Hashimoto's encephalitis) who did not benefit from corticosteroids (Nagpal & Pande, 2004; Hussain et al., 2005). More recently, experiences with plasma treatment have been increasingly reported in patients with seizure disorders with auto-Abs to specific neuronal proteins, such as voltage-gated potassium channels (VGKCs), N-methyl-Daspartate (NMDA) receptors, and glutamic acid decarboxylase (GAD) (Vincent et al., 2004; Florance et al., 2009; Wong et al., 2010). In most case series, likely due to the severity of these syndromes, plasma treatment was carried out in association with other immunotherapy (usually steroids or sequential IVIGs) and the proper effect of the different treatments cannot be exactly specified. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several experimental and clinical studies demonstrated an immunologic basis for different forms of epilepsy. A wide range of immune abnormalities have been reported suggesting the existence of various subtypes of epileptic syndromes with different immunopathogenetic mechanisms. This evidence gives rise to the development of immunologic and immunomodulatory treatments such as usage of steroids, plasmapheresis, and intravenous immunoglobulins, which will be discussed briefly in this article.
    Epilepsia 05/2011; 52 Suppl 3:45-51. DOI:10.1111/j.1528-1167.2011.03036.x · 4.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Die Korrelation zwischen Autoantikörpernachweis, Muster und Schwere der Symptomatik bei Enzephalitiden war richtungsweisend für den Ansatz einer Immuntherapie. Autoantikörper mittels therapeutischer Apherese (Plasmaaustausch [PA], Immunadsorption [IA]) zu entfernen, stellt einen pathophysiologisch begründeten Therapieansatz dar. Ziel war, den aktuellen Einsatz des PA und erstmals auch der IA bei Patienten mit autoimmuner Enzephalitis zu bewerten. Methode Es wurde eine bundesweite Datenerhebung durchgeführt. Die Schwere der neurologischen Symptome wurde vor und nach Apherese anhand der modifizierten Rankin-Skala (mRS) erfasst. Ergebnisse Die Daten von 31 Behandlungsverläufen (30 Patienten, ein Rezidiv) wurden erhoben. Bei 22 Patienten lagen positive Befunde für Autoantikörper vor (NMDAR, GABA, VGKC, Hu). In 23 Fällen wurde die PA, in 7 Fällen die Tryptophan-IA durchgeführt, ein Patient wurde mit beiden Methoden behandelt. In 67% der Verläufe kam es zu einer Verbesserung der mRS-Werte. Der mittlere mRS-Wert aller Patienten betrug vor therapeutischer Apherese 3,2, nach Apherese 2,2 (p < 0,05). Alle mit IA behandelten Patienten besserten sich klinisch von einem mittleren mRS-Wert von 3,9 vor IA auf 1,9 nach IA (p < 0,01). Schlussfolgerung Bei immunvermittelten Enzephalitiden scheint die rasche Entfernung der Autoantikörper mittels PA und IA ein wirksames Therapieprinzip im Rahmen einer kombinierten Immuntherapie zu sein und wird in vielen Kliniken in Deutschland bereits eingesetzt.
    Der Nervenarzt 04/2013; 84(4). DOI:10.1007/s00115-012-3710-7 · 0.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (fourth edition), the subcommittee has incorporated systematic review and evidence-based approach in the grading and categorization of indications. This Fifth ASFA Special Issue has further improved the process of using evidence-based medicine in the recommendations by refining the category definitions and by adding a grade of recommendation based on widely accepted GRADE system. The concept of a fact sheet was introduced in the Fourth edition and is only slightly modified in this current edition. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. The article consists of 59 fact sheets devoted to each disease entity currently categorized by the ASFA as category I through III. Category IV indications are also listed.
    Journal of Clinical Apheresis 01/2010; 25(3):83-177. DOI:10.1002/jca.20240 · 1.58 Impact Factor
Show more